Aurora Cannabis Inc. reported financial results for Q2 fiscal 2025 ended September 30, 2024. Net revenue increased to $81.1 million, up 28.5% YoY. The company achieved positive cash flow from operations before working capital changes of $5.3 million.Medical cannabis revenue grew 41% YoY to $61.3 million, driven by strong international sales. Consumer cannabis revenue declined 12.9% to $10.4 million. Plant propagation revenue from Bevo increased 20.7% to $8.6 million. Gross profit before fair value adjustments rose to $39.2 million from $18.6 million last year.The company reported net income from continuing operations of $1.7 million, compared to $0.4 million in Q2 2024. However, including discontinued operations, Aurora posted a net loss of $13.0 million. As of September 30, 2024, Aurora had $84.9 million in cash and cash equivalents.

Aurora Cannabis Inc. reported financial results for Q2 fiscal 2025 ended September 30, 2024. Net revenue increased to $81.1 million, up 28.5% YoY. The company achieved positive cash flow from operations before working capital changes of $5.3 million.Medical cannabis revenue grew 41% YoY to $61.3 million, driven by strong international sales. Consumer cannabis revenue declined 12.9% to $10.4 million. Plant propagation revenue from Bevo increased 20.7% to $8.6 million. Gross profit before fair value adjustments rose to $39.2 million from $18.6 million last year.The company reported net income from continuing operations of $1.7 million, compared to $0.4 million in Q2 2024. However, including discontinued operations, Aurora posted a net loss of $13.0 million. As of September 30, 2024, Aurora had $84.9 million in cash and cash equivalents.